'Menopause made me forget my name'
Kirsty Dixon's life changed overnight when she started experiencing intense brain fog at 49 years old.
Kirsty, from York, was staring at her screen at work one day, when suddenly she could not remember what she was doing.
"I just asked myself 'What is my name?', and I couldn't even remember my own name.
"I felt like I was going mad, I thought it was only me."
The problems continued when she tried to access support.
"I thought, why aren't people listening to me?
"I've got something really serious going on but I can't get anyone to listen."
Kirsty was told by a doctor that what she had experienced was part of the menopause.
It is estimated that one in three women in the UK is going through the menopause at any given time.
Kirsty, learning and development adviser at the University of York, is working to raise awareness of the lesser-known symptoms and the huge impact they can have on people's lives.
"Before menopause I've always been a very bubbly person, very social, bit mischievous," she said.
"Menopause came along and just put a big thunder cloud over my head.
"I lost myself. The number of times my husband said 'I want my Kirsty back' while he was cuddling me and I was in floods of tears."
Kirsty spent the next four years "fighting it" as she could not believe that those were menopause symptoms.
Then, during lockdown, Kirsty found herself researching menopause for her work.
She stumbled across an article by someone who had experienced the same symptoms as her.
"I got that lightbulb moment that what I was experiencing was perfectly normal, I needed to understand it and know what I could do to help myself," she said.
"I went from having this constant cloud and feeling useless, to actually owning my journey."
Now aged 58, Kirsty runs two support groups for women experiencing the menopause, including a nature walking group around York, and a pop-up cafe in Acomb.
They are non-profit and everyone is welcome, regardless of age or gender.
She hopes the groups will encourage more people to talk about the lesser-known symptoms.
"When you're going through it, it can feel so lonely," she said.
"You feel like it's only you, and you think you're going mad.
"One of the most important things I say to people is get your support network around you, and that's family, friends, and groups like this."
Sarah Mortimer, 54, has been coming to the group since it started in 2022.
She experienced an uncommon symptom of self-diagnosed burning mouth syndrome during her menopause, which involves developing blisters in the mouth with a burning feeling.
"It can be really isolating, so to find groups like this is amazing," she said.
"It makes a huge difference, knowing there's other people going through the same rubbish that you're going through.
"It's that strength in numbers thing, and there's strength in the power of talking about the menopause."
The group is based in York, but people travel from as far as Leeds, Sheffield and Beverley to attend.
Kirsty says that it highlights an ongoing issue around the need for more support for people going through the menopause.
"No one else was running a menopause cafe in York, so it was obviously something that was missing."
She is calling for more groups like this so that people do not have to travel so far to get the support they need.
"What I will say now, is as a post-menopausal woman, I am the most confident, the strongest, most creative person.
"If someone said to me you can have your life again, without your menopause experience, actually, I'd say no, because it's what's made me the person I am today.
"If I can get through that, I can get through anything."
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North or tell us a story you think we should be covering here.
'Fire service is helping me through the menopause'
'I mistook cancer signs for the menopause'
What's the point of the menopause?
NHS menopause advice
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
30 minutes ago
- Medscape
T2D Tied to Mortality in Both Ischemic and Nonischemic HF
TOPLINE: Patients with type 2 diabetes (T2D) had approximately 20%-26% higher mortality rates following ischemic and nonischemic heart failure (HF) than those without diabetes, with similar patterns observed in both women and men. METHODOLOGY: Most epidemiologic studies assessing mortality risk in individuals with HF, categorized by etiology and diabetes status, have relied on clinical trials or hospital data, limiting their generalizability to the broader population. Researchers conducted an observational retrospective cohort study using primary care and hospital data from England to examine the association between T2D and all-cause mortality in patients with ischemic or nonischemic HF. Patients with newly diagnosed T2D were matched with up to four people without diabetes on the basis of sex, birth year, and general practice. Incident HF events were defined as ischemic if they followed an ischemic heart disease event after the diagnosis of T2D; otherwise, they were classified as nonischemic. The outcome of interest was all-cause mortality. A total of 73,344 patients with HF were included, of whom 18,296 had ischemic HF and 55,048 had nonischemic HF. Among patients with ischemic HF, 2806 women (mean age, 77.26 years) and 4447 men (mean age, 73.44 years) had T2D, whereas among those with nonischemic HF, 10,094 women (mean age, 78.33 years) and 9964 men (mean age, 74.83 years) had T2D. TAKEAWAY: During a median follow-up of 2.19 years for ischemic HF and 1.98 years for nonischemic HF, mortality was observed in 52.4% and 57.8% of patients, respectively. Age-standardized mortality rates following ischemic HF were higher in patients with T2D than in those without diabetes (19.2 vs 15.1 and 20.4 vs 16.5 per 100 person-years in women and men, respectively), with similar findings following nonischemic HF in women and men. T2D was associated with higher mortality rates following ischemic HF, with rates 26% higher in women (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.17-1.36) and 23% higher in men (aHR, 1.23; 95% CI, 1.15-1.31). Similarly, following nonischemic HF, T2D was associated with higher mortality rates in both women (aHR, 1.24; 95% CI, 1.19-1.29) and men (aHR, 1.20; 95% CI, 1.15-1.25). IN PRACTICE: 'This [study] highlights the ongoing need to optimize the prevention and management strategies in the overall population of individuals with type 2 diabetes and HF to reduce the risk of premature mortality,' the authors of the study wrote. SOURCE: This study was led by Kajal Panchal, MSc, Leicester Diabetes Centre, University of Leicester, Leicester, England, and was published online in Diabetes, Obesity and Metabolism. LIMITATIONS: This study relied on health records that were collected routinely, which may have introduced measurement errors for certain covariates. The lack of data on echocardiography prevented distinguishing between HF with preserved or reduced ejection fraction. Additionally, confounding variables, such as body fat distribution, dietary factors, and physical activity, were either unavailable or poorly recorded in the databases. DISCLOSURES: This study was funded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration East Midlands. Some authors reported being supported by the funding agency and NIHR Leicester Biomedical Research Centre. One author reported receiving consultancy fees, and another author reported being a consultant or speaker and receiving research grants from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


New York Times
2 hours ago
- New York Times
10 Menopause Myths the Experts Can't Stand
Inescapable hot flashes. Hormonal chaos. Sexless partnerships. Such stereotypes of menopause are deeply ingrained, and few are fully accurate. Menopause can produce symptoms in many parts of the body, and sometimes in unexpected ways, said Rebecca Thurston, an assistant dean for women's health research and a professor of psychiatry at the University of Pittsburgh. We asked gynecologists, endocrinologists, urologists and other experts about the biggest menopause misconceptions they had encountered. Here's what they want patients to know. Myth 1: It's just hot flashes. Hot flashes are a menopausal hallmark: Up to 80 percent of women have them. But numerous lesser-known symptoms are also linked to menopause, including insomnia, mood changes, brain fog, vaginal dryness, joint pain and more. That's largely because menopause is driven by changing levels of estrogen, which affects all tissues. During perimenopause, the years leading up to one's final menstrual period, estrogen fluctuates wildly. After menopause, it settles at a low level. Unfortunately, many people don't know the full range of symptoms this process can cause, said Dr. JoAnn Manson, an endocrinologist and professor at Harvard Medical School. That means they may not realize a symptom is menopause-related, which can mean missing out on helpful treatments. Want all of The Times? Subscribe.
Yahoo
2 hours ago
- Yahoo
Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs
Schizophrenia Drugs Market Dublin, July 07, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market Size, Share & Trends Analysis by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030" report has been added to Schizophrenia Drugs Market was valued at USD 8.19 billion in 2024, and is projected to reach USD 11.20 billion by 2030, rising at a CAGR of 5.60%. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating Drugs Market Report Highlights The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics. The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications. The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition. North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes Report Attribute Details No. of Pages 100 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $8.19 Billion Forecasted Market Value (USD) by 2030 $11.2 Billion Compound Annual Growth Rate 5.6% Regions Covered Global Key Topics CoveredChapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Drug Class and Route of Administration Outlook2.2.2. Distribution Channel Outlook2.2.3. Regional Outlook2.3. Competitive InsightsChapter 3. Schizophrenia Drugs Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/Ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Schizophrenia Drugs Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.1.1. Supplier Power3.3.1.2. Buyer Power3.3.1.3. Substitution Threat3.3.1.4. Threat of New Entrant3.3.1.5. Competitive Rivalry3.3.2. PESTEL Analysis3.3.2.1. Political Landscape3.3.2.2. Technological Landscape3.3.2.3. Economic Landscape3.3.3. Pricing Analysis3.3.4. Pipeline Analysis3.3.4.1. Phase 13.3.4.2. Phase 23.3.4.3. Phase 3Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis4.3. Global Schizophrenia Drugs Market by Class, Revenue4.4. Second-Generation Antipsychotics4.5. Third-Generation Antipsychotics Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue5.4. Oral Antipsychotics5.5. Injectable Antipsychotics Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue6.4. Hospital Pharmacies6.5. Retail Pharmacies6.6. Online Pharmacies6.7. Others Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 20307.3. North America7.4. Europe7.5. Asia-Pacific7.6. Latin America7.7. MEA Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 20248.3.4. Johnson & Johnson Services, Inc.8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.8.3.6. Sumitomo Pharma Co., Ltd.8.3.7. Eli Lilly and Company8.3.8. Alkermes8.3.9. VANDA PHARMACEUTICALS8.3.10. AstraZeneca8.3.11. AbbVie Inc.8.3.12. Pfizer Inc.8.3.13. H. Lundbeck A/S For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Schizophrenia Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio